13F Holdings
中文EN

VERU VERU INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 863894 · Fiscal year ends 09/30

Financial factors as of 2024-09-30 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY3.6%
TTM net income YoY59.4%
TTM EPS YoY—
Revenue 3-yr CAGR-34.9%
Net income 3-yr CAGR—

Margins

Gross margin34.7%
Operating margin-214.2%
Net margin-223.9%
FCF margin-129.3%
EBITDA margin-213.0%

Returns

ROE-145.4%
ROA-68.5%
ROIC (approx.)-327.4%
Asset turnover0.31x

Leverage & solvency

Liabilities / assets46.5%
Debt / equity0.00x
Current ratio2.97x
Interest coverage-59.54x

Cash quality & payout

Operating cash flow / net income0.57x
Accruals ratio-29.2%
Payout ratio—
Capex / revenue0.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-09-30FY20242024-09-30FY20232023-09-30FY20222022-09-30FY20212021-09-30
Income statement
Revenue—$16.89M$16.30M$39.35M$61.26M
Cost of revenue—$11.03M$8.73M$8.76M$13.33M
Gross profit—$5.85M$7.57M$30.59M$47.93M
R&D expense$15.59M$12.78M$51.20M$70.91M$32.69M
SG&A expense$19.94M$24.61M$48.06M$43.18M$20.67M
Operating income-$24.75M-$36.17M-$93.78M-$83.49M$12.97M
Interest expense—$607,470$2.43M$4.37M$4.89M
Pretax income——-$92.67M-$83.80M$4.27M
Income tax$0$0$480,206$236,397-$3.13M
Net income-$22.73M-$37.80M-$93.15M-$84.04M$7.39M
EBITDA-$24.60M-$35.90M-$93.51M-$83.35M$13.07M
EPS (basic)-1.55-2.80-1.10-1.050.10
EPS (diluted)——-1.10-1.050.09
Weighted avg. shares (diluted)——84.97M80.12M83.80M
Balance sheet
Cash & equivalents$15.79M$24.92M$9.63M——
Receivables—$3.96M$4.51M$3.55M$8.79M
Inventory—$4.14M$6.70M$8.62M$5.57M
Current assets$18.92M$35.22M$22.93M$104.00M$151.75M
PP&E, net$364,808$481,372$1.65M$1.19M$592,603
Goodwill$6.88M$6.88M$6.88M$6.88M$6.88M
Intangibles—$0$5,952$3.98M$4.05M
Total assets$29.84M$60.42M$50.02M$135.36M$178.15M
Current liabilities$7.79M$11.87M$17.81M$38.71M$15.77M
Total liabilities$11.50M$28.10M$30.34M$52.56M$25.85M
Shareholders' equity$18.33M$32.32M$19.68M$82.80M$154.52M
Shares outstanding14.65M14.64M91.78M80.51M79.97M
Cash flow statement
Operating cash flow-$30.04M-$21.68M-$88.01M-$47.51M-$15.57M
Capital expenditure$1,083$158,322$665,700$733,052$376,649
Free cash flow-$30.04M-$21.84M-$88.68M-$48.24M-$15.95M
Investing cash flow$25.14M$146,214$6.33M$4.27M$14.62M
Financing cash flow-$4.22M$36.83M$11.11M$1.07M$109.72M
Depreciation & amortization$152,105$268,177$269,874$138,000$98,000
Stock-based compensation$8.10M$13.64M$17.92M$11.24M$5.05M

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.